Literature DB >> 17509986

T-cell and NK-cell posttransplantation lymphoproliferative disorders.

Steven H Swerdlow1.   

Abstract

Posttransplantation lymphoproliferative disorders (PTLDs) of T-cell or natural killer (NK)-cell origin are an uncommon heterogeneous group of lymphoid proliferations that fulfill the criteria for one of the T- or NK-cell lymphomas/leukemias. This report summarizes 130 T/NK-cell PTLDs reported in the literature or presented at the Society for Hematopathology/European Association for Haematopathology Workshop on T/NK-cell malignancies. The T/NK-cell PTLDs occur at a median of 66 months following transplantation and are usually extranodal. The most common types reported are peripheral T-cell lymphoma, unspecified, and hepatosplenic T-cell lymphoma. Approximately one third are Epstein-Barr virus (EBV)+. The median survival is 6 months. EBV+ cases have a significantly longer survival than EBV- cases, even when indolent T-cell large granular lymphocytic leukemias are included among the EBV- cases. Many T/NK-cell PTLDs have been treated with chemotherapy, often together with decreased immunosuppression, but there are infrequent patients who have done well without chemotherapy or radiation.

Entities:  

Mesh:

Year:  2007        PMID: 17509986     DOI: 10.1309/LYXN3RGF7D7KPYG0

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  26 in total

Review 1.  Diagnosis and classification of lymphoma: Impact of technical advances.

Authors:  Elaine S Jaffe
Journal:  Semin Hematol       Date:  2018-05-29       Impact factor: 3.851

2.  Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality?

Authors:  Ly Ma; Youval Katz; Kanu P Sharan; Roland Schwarting; Annette S Kim
Journal:  Int J Clin Exp Pathol       Date:  2010-11-20

Review 3.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 4.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 5.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

6.  Surgical management of perforated gastrointestinal posttransplantation lymphoproliferative disorder after heart transplantation.

Authors:  Hideki Osawa; Mamoru Uemura; Junichi Nishimura; Taishi Hata; Ichiro Takemasa; Tsunekazu Mizushima; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori
Journal:  Int Surg       Date:  2015-02

Review 7.  Epstein Barr virus-associated tumours: an update for the attention of the working pathologist.

Authors:  H-J Delecluse; R Feederle; B O'Sullivan; P Taniere
Journal:  J Clin Pathol       Date:  2007-09-14       Impact factor: 3.411

8.  HIV-related NK/T-cell lymphoma in the brain relapsed during intensive chemotherapy but regressed after chemotherapy discontinuation: the importance of maintaining cellular immunity.

Authors:  Yosuke Nagahata; Aiko Kato; Yukihiro Imai; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2014-06-18       Impact factor: 2.490

9.  Three different histological subtypes of Epstein-Barr virus-negative post-transplant lymphoproliferative disorder in a patient with hepatitis C infection.

Authors:  Mikiko Kobayashi; Naoko Asano; Mana Fukushima; Takayuki Honda
Journal:  Int J Hematol       Date:  2014-05-31       Impact factor: 2.490

Review 10.  Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.

Authors:  Zeina Al-Mansour; Beverly P Nelson; Andrew M Evens
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.